Celebrating initiatives committed to fight against opioid epidemic
On Wednesday morning, the Monroe County commissioners commemorated the one-year anniversary of the Law Enforcement Treatment Initiative (LETI) Program and the 'We Fight Fentanyl' campaign.
LETI and the we fight fentanyl campaign have seen great success in the past year.
Now, the county hopes to continue that momentum.
'Addiction is not prejudiced. It can consume anyone's family and take anyone's life,' said Stephanie Blew in the We Fight Fentanyl Testimonial.
Stephanie from Saylorsburg knows firsthand the devastating effects of addiction; she lost her brother in 2019 and began her journey to overcome the disease nearly six years ago.
Now, she's saving lives by sharing her story as a part of Monroe County's We Fight Fentanyl Campaign.
'For me to put my heart and soul into this campaign is also giving him the justice that he deserved and allowing his memory to still be alive,' Stephanie explained.
The We Fight Fentanyl Campaign also exists in Carbon and Pike counties. In Monroe County, it's celebrating one year alongside the LETI program.
Susquehanna County Correctional Facility closing this month
The two aim to provide tools, treatment, and education to overcome substance use disorder.
'I think we're making a lot of ground with informing people educating them on how to deal with this if it's a loved one or if it's themselves where they can go for help,' said Certified Recovery Specialist Stan Lewandowski.
The programs have resulted in a reduced number of overdose deaths and have connected more than 100 people to the resources they need.
Monroe County is also making strides with its distribution of opioid settlement funds to organizations that help people recover.
'These programs are needed. It's really important for all of these different components and departments to come together,' Justin's House Executive Director Kenneth Ramirez stated.
Kenneth Ramirez is the executive director of Justin's House, a licensed recovery center for men in Monroe County.
The funds gave the organization a new van to break down barriers and transport people to and from life-saving services, helping others get the help they need.
'We do recover,' Ramirez explained.
All of these efforts coming together, to fight for the same cause in the county.
County officials plan to continue the fight by providing opioid settlement funding to more community organizations that support recovery and treatment.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Shaker Heights cheerleader released from hospital weeks after leg amputation
SHAKER HEIGHTS, Ohio (WJW) – The Shaker Heights cheerleader whose leg needed to be amputated after an unthinkable diagnosis celebrated a big milestone on Friday. Amani Smith was released from Rainbow Babies and Children's Hospital, weeks after doctors were forced to amputate her left leg. Amani and her family are thrilled to finally be home, but her major life change is only just beginning. The 17-year-old was at cheerleading camp earlier this summer when she started complaining about a stomach ache. Within hours, she was rushed into emergency surgery. Bernie Kosar not giving up as he waits on liver transplant Doctors at the time discovered a ruptured abdominal cyst and an infection led to sepsis, a potentially deadly condition. She had a stroke during surgery and her parents said a nicked artery during the procedure cut off blood flow to her left leg for hours. Doctors were forced to amputate and she was placed on life support for nearly a week. Now, Amani has recovered enough to return home and her family is navigating the next steps as she is determined to dance again. Big Cleveland weekend: What to know about all the events All the while, the Shaker Heights community has rallied around the family. 'It feels really good. I have a good support group around me,' Amani said. 'After two months and a few days, I'm finally free.' Amani is going into her senior year of high school. So far, a GoFundMe page has raised more than $37,000 for the family, who hopes to get her a prosthetic leg. Learn how to donate right here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Wire
7 hours ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Business Wire
8 hours ago
- Business Wire
QT Imaging Holdings Announces Results of First Annual Stockholder Meeting
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. ('QT Imaging' or the 'Company') (OTCQB: QTIH), a medical device company engaged in the research, development, and commercialization of innovative body imaging systems, announced today that at the Annual Meeting of Company's stockholders (the 'Annual Meeting') held on August 19, 2025, the Company's stockholders voted to approve (i) the election of Daniel Dickson and James Greene as Class I directors to serve until the Company's 2028 Annual Meeting of Stockholders or until their respective successors are elected and qualified, (ii) the appointment of BPM LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 and (iii) an amendment to the Company's Second Amended and Restated Certificate of Incorporation to effect a reverse stock split at a specific ratio within a range of 2:1 to 20:1 to be fixed by the Company's Board of Directors. The Company plans to file the results of the Annual Meeting, as tabulated by an independent inspector of elections, on Form 8-K with the Securities and Exchange Commission today. About QT Imaging Holdings, Inc. QT Imaging is a public medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on the Company, please visit the company's website at
